PD-1とPD-L1阻害剤市場：阻害剤タイプ別、がんタイプ別、流通チャネル別、地域別

世界のPD-1とPD-L1阻害剤市場は、2025年に622億3,000万米ドルと推定され、2032年には2,043億1,000万米ドルに達すると予測され、2025～2032年のCAGRは18.5%で成長する見込みです。

図.PD-1とPD-L1阻害剤市場シェア（%）、2025年地域別

PD-1とPD-L1阻害剤は免疫チェックポイント阻害剤であり、がん治療において有望な結果を示しています。チェックポイント阻害剤は、腫瘍が免疫系の攻撃を回避するのを助けるPD-1とPD-L1と呼ばれるタンパク質をブロックすることにより、身体の自然な抗腫瘍反応を高めるのを助ける。これらのタンパク質をブロックすることで、チェックポイント阻害剤はT細胞と呼ばれる免疫系細胞ががん細胞をより効果的に認識し、攻撃できるようにします。PD-1とPD-L1阻害剤は近年、メラノーマや肺がんなど様々ながんに対する使用が承認されています。従来の治療法と比べて臨床結果が改善したことから、これらの阻害剤の市場は大きく成長しており、今後数年間は高い成長が見込まれています。

市場力学

PD-1とPD-L1阻害剤の世界市場成長の原動力は、世界のがん罹患率の上昇と、有望な臨床的有効性による免疫チェックポイント阻害剤の臨床採用の増加です。さらに、新たなPD-1とPD-L1阻害剤ががんの適応症として承認・上市されたことが、市場の成長をさらに後押ししています。しかし、これらの薬剤の開発・製造にかかるコストの高さや高価な価格設定による市場抑制要因もあり、普及には限界があります。チェックポイント阻害剤と他の抗がん剤との併用療法の可能性を評価する臨床検査が進行中であり、長期的には市場参入者にとって有利な機会となります。

本調査の主要特徴

• 本レポートでは、世界のPD-1とPD-L1阻害剤市場を詳細に分析し、2024年を基準年とした予測期間（2025～2032年）の市場規模と年間平均成長率（CAGR%）を掲載しています。
• また、さまざまなセグメントにわたる潜在的な収益機会を明らかにし、この市場の魅力的な投資提案マトリクスについて解説しています。
• また市場促進要因、抑制要因、機会、新製品の上市や承認、市場動向、地域による展望、主要企業が採用する競争戦略などに関する重要な考察も提供しています。
• 本レポートでは、世界のPD-1とPD-L1阻害剤市場における主要企業プロファイルを、企業ハイライト、製品ポートフォリオ、主要ハイライト、財務実績、戦略などのパラメータに基づいて掲載しています。
• 本レポートから洞察により、マーケティング担当者や企業の経営陣は、将来の製品上市、タイプアップ、市場拡大、マーケティング戦術に関する情報に基づいた意思決定を行うことができます。
• PD-1とPD-L1阻害剤の世界市場レポートは、投資家、サプライヤー、製品メーカー、販売業者、新規参入者、財務アナリストなど、この産業のさまざまな利害関係者を対象としています。
• 利害関係者は、世界のPD-1とPD-L1阻害剤市場分析に使用される様々な戦略マトリックスを通じて、意思決定が容易になります。

目次：

第1章 調査の目的と前提条件

• 調査目的
• 前提条件
• 略語

第2章 市場展望

• レポートの説明
  • 市場の定義と範囲
• エグゼクティブサマリー
• 一貫型機会マップ（COM）

第3章 市場力学、規制、動向分析

• 市場力学
  • がんの発生率/有病率の上昇
  • がん治療の高額な費用
  • 研究開発活動の増加
• 影響分析
• 規制シナリオ
• 製品の発売/承認
• PEST分析
• ポーター分析
• 合併と買収のシナリオ

第4章 世界のPD-1とPD-L1阻害剤市場-コロナウイルス（COVID-19）パンデミックの影響

• COVID-19疫学
• 供給側と需要側の分析
• 経済への影響

第5章 世界のPD-1とPD-L1阻害剤市場、阻害剤タイプ別、2020～2032年

• イントロダクション
• PD-1阻害剤
• PD-L1阻害剤

第6章 世界のPD-1とPD-L1阻害剤市場、がんタイプ別、2020～2032年

• イントロダクション
• 腎臓
• 悪性黒色腫
• 膀胱
• 非小細胞肺がん
• 肝臓
• 頭頸部
• その他

第7章 世界のPD-1とPD-L1阻害剤市場、流通チャネル別、2020～2032年

• イントロダクション
• 病院薬局
• 小売薬局
• オンライン薬局

第8章 世界のPD-1とPD-L1阻害剤市場、地域別、2020～2032年

• イントロダクション
• 北米
• 欧州
• アジア太平洋
• ラテンアメリカ
• 中東
• アフリカ

第9章 競合情勢

• Pfizer Inc.
• Novartis AG
• AstraZeneca PLC
• Gilead Sciences Inc.
• Amgen Inc.
• Sanofi AG
• F. Hoffmann-La Roche AG
• Merck & Co.
• Bristol-Myers Squibb Company
• Regeneron Pharmaceuticals Inc.
• GSK plc
• Ono Pharmaceutical Co., Ltd.
• Eli Lilly and Company
• BeiGene LTD

第10章 アナリストの視点

• 隆盛と衰退
• 一貫型機会マップ

第11章 参考文献と調査手法

• 参考文献
• 調査手法

Global PD-1 and PD-L1 Inhibitor Market is estimated to be valued at USD 62.23 Bn in 2025 and is expected to reach USD 204.31 Bn by 2032, growing at a compound annual growth rate (CAGR) of 18.5% from 2025 to 2032.

Figure. PD-1 And PD-L1 Inhibitor Market Share (%), By Region 2025

PD-1 and PD-L1 inhibitors are immune checkpoint inhibitors that have shown promising results in cancer treatment. Checkpoint inhibitors help boost the body's natural anti-tumor response by blocking proteins called PD-1 and PD-L1 that help tumors evade immune system attacks. By blocking these proteins, checkpoint inhibitors allow the immune system cells called T cells to recognize and attack cancer cells more effectively. Several PD-1 and PD-L1 inhibitors have been approved in recent years for use against various cancers like melanoma, lung cancer and more. With their improved clinical outcomes compared to conventional therapies, the market for these inhibitors has grown substantially and is expected to witness high growth in the coming years.

Market Dynamics:

The global PD-1 and PD-L1 inhibitor market growth is driven by the rising prevalence of cancer worldwide and the increasing adoption of immune checkpoint inhibitors in clinical practice due to their promising clinical efficacy. Moreover, the approval and launch of new PD-1 and PD-L1 inhibitors for additional cancer indications is further fueling the market growth. However, the market faces restraints from the high costs associated with developing and manufacturing these drugs as well as their expensive pricing which limits widespread adoption. Ongoing clinical trials evaluating the potential of combining checkpoint inhibitors with other anticancer therapies presents lucrative opportunities for market players in the long run.

Key Features of the Study:

• This report provides an in-depth analysis of the global PD-1 and PD-L1 inhibitor market, and provides market size (US$ Bn) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year.
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global PD-1 and PD-L1 inhibitor market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
• Key companies covered as a part of this study includes Pfizer Inc., Novartis AG, AstraZeneca PLC, Gilead Sciences Inc., Amgen Inc., Sanofi AG, F. Hoffmann-La Roche AG, Merck & Co., Bristol-Myers Squibb Company, Regeneron Pharmaceuticals Inc., Merck & Co., GSK plc, Ono Pharmaceutical Co., Ltd., Eli Lilly and Company, and BeiGene LTD.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
• The global PD-1 and PD-L1 inhibitor market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global PD-1 and PD-L1 inhibitor market.

Market Segmentation

• Type of Inhibitor:
  • PD-1 Inhibitors
  • PD-L1 Inhibitors
• Cancer Type:
  • Kidney
  • Melanoma
  • Bladder
  • Non-small Cell Lung Cancer
  • Liver
  • Head & neck
  • Others
• Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East
  • Africa
• Company Profiles:
  • Pfizer Inc.
  • Novartis AG
  • AstraZeneca PLC
  • Gilead Sciences Inc.
  • Amgen Inc.
  • Sanofi AG
  • Hoffmann-La Roche AG
  • Merck & Co.
  • Bristol-Myers Squibb Company
  • Regeneron Pharmaceuticals Inc.
  • Merck & Co.
  • GSK plc
  • Ono Pharmaceutical Co., Ltd.
  • Eli Lilly and Company
  • BeiGene LTD

Table of Contents:

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Type of Inhibitor
  • Market Snapshot, By Cancer Type
  • Market Snapshot, By Distribution Channel
  • Market Snapshot, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Rise in incidence/prevalence of cancer
  • High cost of cancer treatment
  • Rise in research and development activities
• Impact Analysis
• Key Highlights
• Regulatory Scenario
• Product launch/Approvals
• PEST Analysis
• PORTER's Analysis
• Merger and Acquisition Scenario

4. Global PD-1 and PD-L1 Inhibitor Market - Impact of Coronavirus (COVID-19) Pandemic

• COVID-19 Epidemiology
• Supply Side and Demand Side Analysis
• Economic Impact

5. Global PD-1 and PD-L1 Inhibitor Market, By Type of Inhibitor, 2020-2032, (US$ Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2020 - 2032
  • Segment Trends
• PD-1 Inhibitors
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
• PD-L1 Inhibitors
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)

6. Global PD-1 and PD-L1 Inhibitor Market, By Cancer Type, 2020-2032, (US$ Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2020 - 2032
  • Segment Trends
• Kidney
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
• Melanoma
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
• Bladder
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
• Non-small Cell Lung Cancer
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
• Liver
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
• Head & Neck
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)

7. Global PD-1 and PD-L1 Inhibitor Market, By Distribution Channel, 2020-2032, (US$ Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2020 - 2032
  • Segment Trends
• Hospital Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
• Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
• Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)

8. Global PD-1 and PD-L1 Inhibitor Market, By Region, 2020-2032, (US$ Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2020 - 2032
  • Segment Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type of Inhibitor, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (US$ Bn)
  • U.S.
  • Canada
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type of Inhibitor, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (US$ Bn)
  • U.K.
  • Germany
  • Italy
  • France
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type of Inhibitor, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (US$ Bn)
  • China
  • India
  • Japan
  • ASEAN
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type of Inhibitor, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (US$ Bn)
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type of Inhibitor, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (US$ Bn)
  • GCC
  • Israel
  • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type of Inhibitor, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2020 - 2032, (US$ Bn)
  • North Africa
  • Central Africa
  • South Africa

9. Competitive Landscape

• Pfizer Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Novartis AG
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• AstraZeneca PLC
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Gilead Sciences Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Amgen Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Sanofi AG
• F. Hoffmann-La Roche AG
• Merck & Co.
• Bristol-Myers Squibb Company
• Regeneron Pharmaceuticals Inc.
• GSK plc
• Ono Pharmaceutical Co., Ltd.
• Eli Lilly and Company
• BeiGene LTD

10. Analyst View

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

11. References and Research Methodology

• References
• Research Methodology
• About us and Sales Contact